# Cava Group, Inc.: financial statements, quarterly

CAVA · NYSE · CIK 1639438 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 27

Pages: [Overview](/companies/cava.md) · [Financials](/companies/cava/financials.md) · [Filings](/companies/cava/filings.md) · [Insiders](/companies/cava/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cava/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2022-10-02) | period not labelled (2022-12-25) | Q2 FY2023 (2023-07-09) | Q3 FY2023 (2023-10-01) | Q4 FY2023 (2023-12-31) | Q2 FY2024 (2024-07-14) | Q3 FY2024 (2024-10-06) | Q4 FY2024 (2024-12-29) | Q2 FY2025 (2025-07-13) | Q3 FY2025 (2025-10-05) | Q4 FY2025 (2025-12-28) | Q2 FY2026 (2026-07-12) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [139](/filings/0001628280-23-037474.md) | [130 d](/filings/0001628280-25-007882.md) | [173](/filings/0001628280-24-038276.md) | [176](/filings/0001628280-24-047336.md) | [177 d](/filings/0001628280-26-011296.md) | [233](/filings/0001639438-25-000007.md) | [244](/filings/0001628280-25-049080.md) | [227 d](/filings/0001628280-26-011296.md) | [281](/filings/0001628280-26-055864.md) | [292](/filings/0001628280-25-049080.md) | [275 d](/filings/0001628280-26-011296.md) | [368](/filings/0001628280-26-055864.md) |
| Gross profit | $m | [26.4](/filings/0001628280-23-037474.md) | [23.8 d](/filings/0001628280-24-007277.md) | [45.4](/filings/0001628280-24-038276.md) | [44.5](/filings/0001628280-24-047336.md) | [39.9 d](/filings/0001628280-24-007277.md) | [62.4](/filings/0001628280-24-038276.md) | [62.6](/filings/0001628280-24-047336.md) | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [16.5](/filings/0001628280-23-037474.md) | [16.3 d](/filings/0001628280-25-007882.md) | [23.3](/filings/0001628280-24-038276.md) | [24.5](/filings/0001628280-24-047336.md) | [24.7 d](/filings/0001628280-26-011296.md) | [28.3](/filings/0001639438-25-000007.md) | [29.8](/filings/0001628280-25-049080.md) | [28.5 d](/filings/0001628280-26-011296.md) | [32.1](/filings/0001628280-26-055864.md) | [31.5](/filings/0001628280-25-049080.md) | [32.5 d](/filings/0001628280-26-011296.md) | [39.8](/filings/0001628280-26-055864.md) |
| Operating income | $m | [(12.2)](/filings/0001628280-23-037474.md) | [(19.3) d](/filings/0001628280-25-007882.md) | [5.8](/filings/0001628280-24-038276.md) | [2.8](/filings/0001628280-24-047336.md) | [(1.6) d](/filings/0001628280-26-011296.md) | [16.1](/filings/0001639438-25-000007.md) | [13.8](/filings/0001628280-25-049080.md) | [4.0 d](/filings/0001628280-26-011296.md) | [19.6](/filings/0001628280-26-055864.md) | [17.1](/filings/0001628280-25-049080.md) | [2.8 d](/filings/0001628280-26-011296.md) | [26.8](/filings/0001628280-26-055864.md) |
| Income tax | $m | [(0.0)](/filings/0001628280-23-037474.md) | [0.0 d](/filings/0001628280-25-007882.md) | [0.0](/filings/0001628280-24-038276.md) | [0.0](/filings/0001628280-24-047336.md) | [0.7 d](/filings/0001628280-26-011296.md) | [0.3](/filings/0001639438-25-000007.md) | [(0.1)](/filings/0001628280-25-049080.md) | [(70.9) d](/filings/0001628280-26-011296.md) | [5.3](/filings/0001628280-26-055864.md) | [5.9](/filings/0001628280-25-049080.md) | [1.2 d](/filings/0001628280-26-011296.md) | [7.6](/filings/0001628280-26-055864.md) |
| Net income | $m | [(11.9)](/filings/0001628280-23-037474.md) | [(18.8) d](/filings/0001628280-25-007882.md) | [6.5](/filings/0001628280-24-038276.md) | [6.8](/filings/0001628280-24-047336.md) | [2.0 d](/filings/0001628280-26-011296.md) | [19.7](/filings/0001639438-25-000007.md) | [18.0](/filings/0001628280-25-049080.md) | [78.6 d](/filings/0001628280-26-011296.md) | [18.4](/filings/0001628280-26-055864.md) | [14.7](/filings/0001628280-25-049080.md) | [4.9 d](/filings/0001628280-26-011296.md) | [23.0](/filings/0001628280-26-055864.md) |
| Diluted EPS | $ per share | [(8.96)](/filings/0001628280-23-037474.md) | not reported | [0.21](/filings/0001628280-24-038276.md) | [0.06](/filings/0001628280-24-047336.md) | not reported | [0.17](/filings/0001639438-25-000007.md) | [0.15](/filings/0001628280-25-049080.md) | not reported | [0.16](/filings/0001628280-26-055864.md) | [0.12](/filings/0001628280-25-049080.md) | not reported | [0.19](/filings/0001628280-26-055864.md) |
| Basic EPS | $ per share | [(8.96)](/filings/0001628280-23-037474.md) | not reported | [0.23](/filings/0001628280-24-038276.md) | [0.06](/filings/0001628280-24-047336.md) | not reported | [0.17](/filings/0001639438-25-000007.md) | [0.16](/filings/0001628280-25-049080.md) | not reported | [0.16](/filings/0001628280-26-055864.md) | [0.13](/filings/0001628280-25-049080.md) | not reported | [0.20](/filings/0001628280-26-055864.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-10-01) | FY2023 (2023-12-31) | Q1 FY2024 (2024-04-21) | Q2 FY2024 (2024-07-14) | Q3 FY2024 (2024-10-06) | FY2024 (2024-12-29) | Q1 FY2025 (2025-04-20) | Q2 FY2025 (2025-07-13) | Q3 FY2025 (2025-10-05) | FY2025 (2025-12-28) | Q1 FY2026 (2026-04-19) | Q2 FY2026 (2026-07-12) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [340](/filings/0001628280-23-037474.md) | [332](/filings/0001628280-25-007882.md) | [329](/filings/0001628280-24-025487.md) | [344](/filings/0001628280-24-038276.md) | [367](/filings/0001628280-24-047336.md) | [366](/filings/0001628280-26-011296.md) | [289](/filings/0001628280-25-026077.md) | [290](/filings/0001639438-25-000007.md) | [285](/filings/0001628280-25-049080.md) | [283](/filings/0001628280-26-055864.md) | [296](/filings/0001628280-26-036625.md) | [323](/filings/0001628280-26-055864.md) |
| Current assets | $m | [364](/filings/0001628280-23-037474.md) | [355](/filings/0001628280-25-007882.md) | [352](/filings/0001628280-24-025487.md) | [370](/filings/0001628280-24-038276.md) | [393](/filings/0001628280-24-047336.md) | [394](/filings/0001628280-26-011296.md) | [403](/filings/0001628280-25-026077.md) | [419](/filings/0001639438-25-000007.md) | [425](/filings/0001628280-25-049080.md) | [431](/filings/0001628280-26-055864.md) | [445](/filings/0001628280-26-036625.md) | [480](/filings/0001628280-26-055864.md) |
| Total assets | $m | [985](/filings/0001628280-23-037474.md) | [984](/filings/0001628280-25-007882.md) | [1,005](/filings/0001628280-24-025487.md) | [1,039](/filings/0001628280-24-038276.md) | [1,080](/filings/0001628280-24-047336.md) | [1,170](/filings/0001628280-26-011296.md) | [1,228](/filings/0001628280-25-026077.md) | [1,292](/filings/0001639438-25-000007.md) | [1,322](/filings/0001628280-25-049080.md) | [1,360](/filings/0001628280-26-055864.md) | [1,423](/filings/0001628280-26-036625.md) | [1,500](/filings/0001628280-26-055864.md) |
| Current liabilities | $m | [113](/filings/0001628280-23-037474.md) | [109](/filings/0001628280-25-007882.md) | [111](/filings/0001628280-24-025487.md) | [124](/filings/0001628280-24-038276.md) | [134](/filings/0001628280-24-047336.md) | [133](/filings/0001628280-26-011296.md) | [134](/filings/0001628280-25-026077.md) | [154](/filings/0001639438-25-000007.md) | [158](/filings/0001628280-25-049080.md) | [163](/filings/0001628280-26-055864.md) | [168](/filings/0001628280-26-036625.md) | [193](/filings/0001628280-26-055864.md) |
| Total liabilities | $m | [419](/filings/0001628280-23-037474.md) | [413](/filings/0001628280-25-007882.md) | [424](/filings/0001628280-24-025487.md) | [443](/filings/0001628280-24-038276.md) | [463](/filings/0001628280-24-047336.md) | [474](/filings/0001628280-26-011296.md) | [502](/filings/0001628280-25-026077.md) | [541](/filings/0001639438-25-000007.md) | [553](/filings/0001628280-25-049080.md) | [580](/filings/0001628280-26-055864.md) | [613](/filings/0001628280-26-036625.md) | [658](/filings/0001628280-26-055864.md) |
| Shareholders' equity | $m | [566](/filings/0001628280-24-047336.md) | [571](/filings/0001628280-26-011296.md) | [581](/filings/0001639438-25-000007.md) | [595](/filings/0001628280-25-049080.md) | [616](/filings/0001628280-25-049080.md) | [696](/filings/0001628280-26-055864.md) | [726](/filings/0001628280-26-055864.md) | [751](/filings/0001628280-26-055864.md) | [769](/filings/0001628280-25-049080.md) | [780](/filings/0001628280-26-055864.md) | [810](/filings/0001628280-26-055864.md) | [841](/filings/0001628280-26-055864.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2022-10-02) | period not labelled (2022-12-25) | Q3 FY2023 (2023-10-01) | Q4 FY2023 (2023-12-31) | Q3 FY2024 (2024-10-06) | Q4 FY2024 (2024-12-29) | Q3 FY2025 (2025-10-05) | Q4 FY2025 (2025-12-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [6.7 d](/filings/0001628280-23-037474.md) | [0.8 d](/filings/0001628280-25-007882.md) | [26.0 d](/filings/0001628280-24-047336.md) | [24.0 d](/filings/0001628280-26-011296.md) | [43.9 d](/filings/0001628280-25-049080.md) | [29.9 d](/filings/0001628280-26-011296.md) | [45.6 d](/filings/0001628280-25-049080.md) | [40.3 d](/filings/0001628280-26-011296.md) |
| Capital expenditure | $m | [26.1 d](/filings/0001628280-23-037474.md) | [32.4 d](/filings/0001628280-25-007882.md) | [35.1 d](/filings/0001628280-24-047336.md) | [31.2 d](/filings/0001628280-26-011296.md) | [20.5 d](/filings/0001628280-25-049080.md) | [27.7 d](/filings/0001628280-26-011296.md) | [44.3 d](/filings/0001628280-25-049080.md) | [37.4 d](/filings/0001628280-26-011296.md) |
| Share repurchases | $m | [0.0 d](/filings/0001628280-23-037474.md) | [0.3 d](/filings/0001628280-24-007277.md) | [0.1 d](/filings/0001628280-23-037474.md) | [1.5 d](/filings/0001628280-24-007277.md) | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2022-07-10) | period not labelled (2022-10-02) | Q2 FY2023 (2023-07-09) | Q3 FY2023 (2023-10-01) | Q2 FY2024 (2024-07-14) | Q3 FY2024 (2024-10-06) | Q2 FY2025 (2025-07-13) | Q3 FY2025 (2025-10-05) | Q2 FY2026 (2026-07-12) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.3](/filings/0001628280-23-029592.md) | [1.3](/filings/0001628280-23-037474.md) | [31.3](/filings/0001628280-24-038276.md) | [118](/filings/0001628280-24-047336.md) | [118](/filings/0001639438-25-000007.md) | [118](/filings/0001628280-25-049080.md) | [118](/filings/0001628280-26-055864.md) | [118](/filings/0001628280-25-049080.md) | [118](/filings/0001628280-26-055864.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 116,806,198 at 2026-08-04, from the cover of the [10-Q filed 2026-08-12](/filings/0001628280-26-055864.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.